by Stacey Johnson | Jul 29, 2016
It was Science magazine’s 2013 breakthrough of the year and called a “turning point in cancer.” It even scored its own awareness month that year. Cancer immunotherapy – therapies that harness the power of a patient’s immune system to fight their disease – had...
by Mark Curtis | Jun 30, 2016
Welcome to your update from the clinic for the month of May. Long-standing industry pioneer StemCells, Inc. decided to wind down its operations after a failed Phase 2 study in spinal cord injury. Aduro Biotech also saw a failure with its GVAX product in pancreatic...
by James Smith | Jun 28, 2016
This post was authored by Kelvin Ng and James Smith. Completing his PhD this year in the Karp lab at MIT/Harvard, Kelvin focuses on strategies and technologies that guide or accelerate the translation of therapeutic extracellular vesicles. His multidisciplinary...
by Mark Curtis | Jun 23, 2016
Welcome to your deal review for the month of May. Intellia Therapeutics went public this past month giving investors a second shot on net if they want to gain exposure to gene editing technologies. Caladrius Biosciences spun-out its cell-based immunotherapy to AiVita...
by Stacey Johnson | Jun 3, 2016
Have you ever wanted to shed your skin? I don’t mean in the metaphorical sense like becoming a different person, free of all the old baggage we accumulate in life. And I’m not talking about CCRM’s new logo and colours either, but thanks for noticing. (Shameless.) I...
by Stacey Johnson | May 27, 2016
The subway map is a popular metaphor for showing how to get from point A to point B with many stops along the way. It can be simple, with only a few intersecting lines of tracks – Toronto’s (shockingly inadequate) two-line system comes to mind – or complicated, like...
Comments